Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

A Nebraska woman says she’s still in shock after being terminated from the FDA in mid-February. Federal layoffs have been ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Capricor Therapeutics (CAPR) announced the U.S. Food and Drug Administration has accepted for review its Biologics License Application seeking ...

President Sheinbaum discussed her high approval rating, formal sector jobs growth and recent extraditions, at her Monday ...

Often when Trump picks fights abroad he seems to give a significant political boost to his antagonists. We’re living through ...

Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains 'Buy' with 22% upside potential. Read ...

Zynex specializes in non-invasive pain management and patient monitoring, with promising advancements. Read why I think ZYXI ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

Deutsche Bank analyst David Hoang initiated coverage on Biohaven with a Buy rating and a price target ... stage clinical assets," Hoang stated. The FDA's decision to grant Priority Review to ...